12:00 AM
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Sonazoid perflubutane: Development discontinued

Daiichi said in its earnings for the first 6 months of its fiscal year ending March 31, 2013, that it discontinued development of perflubutane in prostate cancer after the product did not...

Read the full 137 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >